Annemiek Walenkamp

Medical Oncologist, Associate Professor Profile

Medical Oncologist, Associate Professor

My work focuses on brain and neuroendocrine tumours, with the main research lines: rare cancers with special interest in neuroendocrine tumors and neuro-oncology, effects of physical activity during cancer treatment and chemokines and their receptors.
Research involves the exploration of novel rational cancer treatment options including lifestyle changes, to enhance therapeutic efficacy and personalized medicine, in interdisciplinary and translational research.
Next to being the head of the European Neuroendicrine Tumor Society Center of Excellence (ENETS) and my position as principal investigator of multiple clinical studies, I lead the national biobank for rare cancers (FORCE), also supervise PhD students and teach medical students of various training programme.

Discover our research

publication

Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial

2024, Neuro-Oncology

publication

Cancer survivors' experiences of a physical activity program in primary care: a qualitative study

2024, Journal of cancer survivorship-Research and practice

All publications

- The value of circulating tumour DNA in neuroendocrine neoplasmsAnnemiek Walenkamp-Hageman (Invited speaker) 14-Sep-2024 Professional or public presentation > Professional
- College ter Beoordeling van Geneesmiddelen (External organisation)Annemiek Walenkamp-Hageman (Please select a role) 2023 → Membership > Professional
- Role of (international) biobanking in rare cancer researchAnnemiek Walenkamp-Hageman (Invited speaker) 17-Nov-2022 Professional or public presentation > Professional
- Follow-up of NETAnnemiek Walenkamp-Hageman (Invited speaker) 15-Jul-2022 Professional or public presentation > Professional
- How to proceed with national biobanking in rare cancer researchAnnemiek Walenkamp-Hageman (Invited speaker) 2022 Professional or public presentation > Professional
All activities
- UMCG Awarded ENETS Center of Excellence for Tumorgroup NET/NECAnnemiek Walenkamp-Hageman, 2022 Professional
- Infrastructural grant FORCE; Infrastructure for rare cancer in the Netherlands (€3.200.000,--)Annemiek Walenkamp-Hageman, 2021 Academic
- Educational grant IPSEN: “Multi-disciplinary website to inform patients with neuroendocrine tumors”. PI. (€50.000,--)Annemiek Walenkamp-Hageman, 2020 Academic
- Grant: UMCG Cancer Researchfund: “Non-invasive evaluation of oxidative muscle metabolism in patients with testicular cancer enrolled in the UMCG ACT trial” (€3.000,--)Annemiek Walenkamp-Hageman, 2020 Academic
- Educational grant IPSEN: “Multi-disciplinary approach in neuroendocrine tumor patients”. PI. (€200.000,--)Annemiek Walenkamp-Hageman, 2017 Academic
All prizes

Annemiek Walenkamp

Discover our research

Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial

Cancer survivors' experiences of a physical activity program in primary care: a qualitative study

Contact

Footer navigatie

UMCG Research

Researchers

About UMCG

Annemiek Walenkamp

Discover our research

Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial

Cancer survivors' experiences of a physical activity program in primary care: a qualitative study

Activities

Prizes

Contact

UMCG Research

Researchers

About UMCG